Uncovering actionable genetic alterations and immune predictive biomarkers for anal squamous cell carcinomas in the era of immunotherapy PD-L1 and Beyond | Caris Life Sciences
Home / Research / Publications / Uncovering actionable genetic alterations and immune predictive biomarkers for anal squamous cell carcinomas in the era of immunotherapy PD-L1 and Beyond

Publications

Uncovering actionable genetic alterations and immune predictive biomarkers for anal squamous cell carcinomas in the era of immunotherapy PD-L1 and Beyond

Background:

Squamous cell carcinoma of the anal canal (SCAC) is a rare cancer with limited effective treatments. Immune checkpoint inhibitors (ICIs) use is routine for recurrent/refractory disease, but predictive biomarkers remain elusive. We analyzed the largest dataset of SCAC to date, focusing on PD-L1 expression.

Download Publication
Learn More
Name(Required)